Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Authors:
  • MMMarcus A. Mall
    Marcus A. Mall
  • PDPavel Dřevínek
    Pavel Dřevínek
  • LLLarry C. Lands
    Larry C. Lands
  • EMEdward F. McKone
    Edward F. McKone
  • DPDeepika Polineni
    Deepika Polineni
  • BRBonnie W. Ramsey
    Bonnie W. Ramsey
  • JTJennifer L. Taylor-Cousar
    Jennifer L. Taylor-Cousar
  • ETElizabeth Tullis
    Elizabeth Tullis
  • FVFrançois Vermeulen
    François Vermeulen
  • GMGautham Marigowda
    Gautham Marigowda
  • CMCharlotte M. McKee
    Charlotte M. McKee

Abstract
Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation. In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del–minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clinical outcomes.
Funding Information
  • Vertex Pharmaceuticals Incorporated

This publication has 30 references indexed in Scilit: